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ABSTRACT
OBJECTIVES The aim of this study was to evaluate 1-year outcomes of valve–in–mitral annular calcification (ViMAC) in
the MITRAL (Mitral Implantation of Transcatheter Valves) trial.
BACKGROUND The MITRAL trial is the first prospective study evaluating the feasibility of ViMAC using balloon-
expandable aortic transcatheter heart valves.
METHODS A multicenter prospective study was conducted, enrolling high-risk surgical patients with severe mitral
annular calcification and symptomatic severe mitral valve dysfunction at 13 U.S. sites.
RESULTS Between February 2015 and December 2017, 31 patients were enrolled (median age 74.5 years [interquartile
range (IQR): 71.3 to 81.0 years], 71% women, median Society of Thoracic Surgeons score 6.3% [IQR: 5.0% to 8.8%],
87.1% in New York Heart Association functional class III or IV). Access was transatrial (48.4%), transseptal (48.4%), or
transapical (3.2%). Technical success was 74.2%. Left ventricular outflow tract obstruction (LVOTO) with hemodynamic
compromise occurred in 3 patients (transatrial, n ¼ 1; transseptal, n ¼ 1; transapical, n ¼ 1). After LVOTO occurred in the
first 2 patients, pre-emptive alcohol septal ablation was implemented to decrease risk in high-risk patients. No intra-
procedural deaths or conversions to open heart surgery occurred during the index procedures. All-cause mortality at
30 days was 16.7% (transatrial, 21.4%; transseptal, 6.7%; transapical, 100% [n ¼ 1]; p ¼ 0.33) and at 1 year was 34.5%
(transatrial, 38.5%; transseptal, 26.7%; p ¼ 0.69). At 1-year follow-up, 83.3% of patients were in New York Heart
Association functional class I or II, the median mean mitral valve gradient was 6.1 mm Hg (IQR: 5.6 to 7.1 mm Hg), and all
patients had #1þ mitral regurgitation.
CONCLUSIONS At 1 year, ViMAC was associated with symptom improvement and stable transcatheter heart valve per-
formance. Pre-emptive alcohol septal ablation may prevent transcatheter mitral valve replacement–induced LVOTO in pa-
tients at risk. Thirty-daymortality ofpatients treatedvia transseptal accesswas lower thanpredictedby theSocietyofThoracic
Surgeons score. Further studies are needed to evaluate safety and efficacy of ViMAC. (J AmColl Cardiol Intv 2021;14:830–45)
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P atients with severe mitral annular calcification(MAC) are at high risk for conventional mitralvalve (MV) surgery because they often have
multiple comorbid conditions, and the calcium burden
makes the procedure technically challenging, preclud-
ing a successful outcome for many (1–3).
Transcatheter MV replacement (TMVR) with the
off-label use of aortic balloon-expandable trans-
catheter heart valves (THVs) has been used as an
alternative to conventional MV surgery. Data on the
early experience with these procedures were collected
in 2 TMVR retrospective registries, which showed 25%
to 35% all-cause mortality at 30 days and 54% to 63% at
1 year (4,5). In these registries, left ventricular outflow
tract obstruction (LVOTO) with hemodynamic
compromise occurred in 11% to 40% of patients and
was associated with poor outcomes. Alcohol septal
ablation was shown to reduce TMVR-induced left
ventricular outflow tract (LVOT) gradient acutely and
has been a lifesaving rescue option (6). Pre-emptive
use of alcohol ablation as a strategy to decrease the
risk for TMVR-induced LVOTO had not been used
prospectively before the clinical trial we describe
herein. The MAC arm of the MITRAL (Mitral Implan-
tation of Transcatheter Valves) trial is a prospective
single-arm study, which was designed to evaluate the
safety and feasibility of TMVR with a balloon-
expandable THV to treat patients with severe MAC at
high surgical risk. This trial allowed the pre-emptive
use of alcohol ablation to decrease the risk for
TMVR-induced LVOTO in patients at risk. Herein, we
present 30-day and 1-year outcomes of patients in the
MAC arm of the MITRAL trial.
METHODS
This study was conducted following ethical principles
according to the Declaration of Helsinki as well as U.S.
Food and Drug Administration guidelines (Code of
Federal Regulations Title 21, Part 812, and Good Clin-
ical Practices recommended by the International Or-
ganization for Standardization [ISO 14155:2011]). The
study was approved by the Mayo Clinic Institutional
Review Board and the respective Institutional Review
Boards of the participating institutions. All
patients provided written informed consent.
STUDY DESIGN AND PATIENTS. The MITRAL
trial early feasibility study is a physician-
initiated, prospective, multicenter clinical
trial (IDE G140136; NCT02370511) designed to
evaluate the safety and feasibility of TMVR
using the SAPIEN XT and SAPIEN 3 valves
(Edwards Lifesciences, Irvine, California). The
study has 3 treatment arms: 1) native MV dis-
ease with MAC, treated with valve-in-MAC
(ViMAC) (n ¼ 31); 2) failing MV annuloplasty
ring, treated with mitral valve-in-ring
(n ¼ 30); and 3) failed surgical bioprostheses,
treated withmitral valve-in-valve (n¼ 30). We
report the results of the MAC arm.
Patients at high surgical risk were consid-
ered eligible for the study if they had severe
MAC with severe mitral stenosis (MS) or se-
vere mitral regurgitation (MR) with at least
moderate MS and symptoms of New York
Heart Association functional class II or
greater. Inclusion and exclusion criteria are
listed in Supplemental Appendix 1. Clinical informa-
tion and cardiac imaging for study candidates were
presented in a live case-review conference call to an
eligibility committee.
During the course of the study, we observed that a
TMVR-induced LVOT gradient could recur the day
after successful alcohol septal ablation was per-
formed to treat acute LVOTO. The suspected mecha-
nism for recurrence was septal edema. This finding
led to the hypothesis that pre-emptive alcohol septal
ablation to prevent LVOTO in patients at risk could be
a better strategy if performed days or weeks before
TMVR to avoid the acute phase, when septal edema
may occur. After this observation was made, patients
who were not accepted into the study because of high
risk for LVOTO were given the option of pre-emptive
septal ablation with case reconsideration after follow-
up computed tomographic (CT) imaging 3 to 4 weeks
after alcohol ablation. The outcomes of patients un-
dergoing septal ablation outside the trial were not
collected.
SEE PAGE 873
AB BR E V I A T I O N S
AND ACRONYM S
CT = computed tomographic
IQR = interquartile range
LAMPOON = intentional
laceration of the anterior mitral
leaflet to prevent left
ventricular outflow tract
obstruction
LVOT = left ventricular
outflow tract
LVOTO = left ventricular
outflow tract obstruction
MAC = mitral annular
calcification
MR = mitral regurgitation
MS = mitral stenosis
MV = mitral valve
THV = transcatheter heart
valve
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Baseline echocardiographic and CT studies were
analyzed by independent core laboratories. Clinical
events were adjudicated by an independent clinical
events committee, and safety was monitored by a
data and safety monitoring board (Supplemental
Appendix 2).
PROCEDURES. Transthoracic and transesophageal
echocardiography were performed according to pub-
lished guidelines and analyzed at an independent
core laboratory according to American Society of
Echocardiography standards (7). The cardiac CT im-
age acquisition protocol was similar to CT protocols
for transcatheter aortic valve replacement (8), with
adjustments for MV analysis (9), summarized in
Supplemental Appendix 3 and illustrated in Figure 1.
Transseptal, transapical, and open transatrial
approaches were allowed. Access type was selected
according to anatomy, with transseptal preferred for
patients with favorable anatomy.
Details of the delivery access type selection and
technique are provided in Supplemental Appendix 4.
OUTCOMES. The primary safety endpoint was tech-
nical success at exit from the catheterization labora-
tory or operating room, defined as successful delivery
and retrieval of the transcatheter delivery system,
deployment of a single valve in the correct position in
the mitral annulus, adequate performance of the
transcatheter valve including a mean MV
gradient <10 mm Hg and residual MR <2þ, no need
for surgery or additional reintervention, and patient’s
departure from the procedure room alive. The pri-
mary performance endpoint was absence of MR grade
FIGURE 1 Cardiac Computed Tomographic Analysis
Measurements of a calcified mitral annulus, made with (A) Vitrea (Vital Images, Minnetonka, Minnesota, USA), and (B) 3mensio Structural Heart Workflow version 8.1
(Pie Medical Imaging, Maastricht, the Netherlands). The mitral valve “neo-annulus” area measurement is shown from the surgeon’s short-axis view during diastole
(D-shape method). (C-D) A virtual THV is placed in the mitral annulus (pink), size selected according to annulus area. (E-F) Neo-LVOT measurement using Mimics,
Materialise, Leuven Belgium. (G) Virtual valve visualized in the LVOT long-axis view. The LVOT space is measured where the THV stent frame is closest to the septum
(arrow). (H) Neo-LVOT area measurement shown in short-axis view during systole. After placing the virtual valve (pink), the remaining LVOT area is measured
(arrow). (I) Fluoroscopy simulation shows a coplanar view of the mitral annulus, used to determine the valve deployment angle during valve implantation. (J) A virtual
valve is placed 80% ventricular and 20% atrial across the mitral annulus. Radiopaque landmarks such as calcium (arrow) are often used as surrogates to determine the
landing zone of the ventricular edge of the THV stent during implantation. (K,L) Images after TMVR show the THV 80% ventricular and 20% atrial across the
mitral annulus. CAU ¼ caudal; CRA ¼ cranial; RAO ¼ right anterior oblique.
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2þ or greater or mean MV gradient $10 mm Hg at
30 days and 1 year. Secondary safety endpoints
included procedural success and all-cause mortality
at 30 days and 1 year. Definitions and a complete list
of secondary endpoints are provided in Supplemental
Appendix 5.
STATISTICAL ANALYSIS. Continuous variables are
summarized as median (interquartile range [IQR]).
Categorical variables are presented as frequencies
and percentages. Only 1 patient was treated via
transapical access. Therefore, we did not include this
patient’s data in the group comparison, which was
between transseptal and transatrial cases. Compari-
sons between discrete groups were made using the
Fisher exact test. Comparisons of continuous vari-
ables between groups were made using Kruskal-
Wallis 1-way analysis of variance on ranks. For com-
parisons between time points, a Wilcoxon test was
used. These comparisons included only patients with
values at both time points. A Kaplan-Meier curve was
generated for all-cause mortality, and treatment arms
were compared using the log-rank test. All p values
were 2-sided, and values <0.05 were considered to
indicate statistical significance. All analyses were
conducted using R version 3.4.2 (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
Between February 2015 and December 2017, 92 pa-
tients were screened and their cases presented at
case-review conference calls for eligibility determi-
nation. Of these patients, 61 were excluded because
of high risk for LVOTO (n ¼ 29), embolization (n ¼ 16),
or both (n ¼ 16). These patients were not treated with
transatrial ViMAC, because they were not candidates
for surgery or they refused surgery. Similarly, they
were not treated with pre-emptive alcohol septal
ablation, because of clinical or anatomic characteris-
tics that made them not ideal candidates, or the local
site preferred other options. A total of 31 patients
were enrolled (Figure 2). Baseline clinical character-
istics are described in Table 1. Briefly, the patients’
median age was 74.5 years (IQR: 71.3 to 81.0 years),
71% were women, and they had multiple comorbid
conditions, including 51.6% with prior aortic valve
FIGURE 2 Patient Flowchart
DNR ¼ do not resuscitate; MAC ¼ mitral annular calcification; MOF ¼ multiple organ failure; LVOTO ¼ left ventricular outflow tract obstruction; STS ¼ Society of
Thoracic Surgeons; THV ¼ transcatheter heart valve; TMVR ¼ transcatheter mitral valve replacement; ViMAC ¼ valve–in–mitral annular calcification; VSD ¼ ventricular
septal defect.
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(n ¼ 15) p Value†
Age (yrs) 74.5 (71.3–81.0) 78.0 (73.5–81.5) 72.0 (68.5–79.5) 0.22
Female 22/31 (71.0) 12/15 (80.0) 9/15 (60.0) 0.43
Diabetes 12/31 (38.7) 7/15 (46.7) 5/15 (33.3) 0.71
Atrial fibrillation 13/31 (41.9) 7/15 (46.7) 6/15 (40.0) 1.00
Chronic kidney disease 9/31 (29.0) 3/15 (20.0) 6/15 (40.0) 0.43
Chronic obstructive pulmonary disease 15/31 (48.4) 6/15 (40.0) 8/15 (53.3) 0.72
Home oxygen therapy 7/31 (22.6) 2/15 (13.3) 4/15 (26.7) 0.65
Receiving long-term anticoagulation 9/31 (29.0) 2/15 (13.3) 7/15 (46.7) 0.11
Hospitalization for heart failure during prior 12 months 14/31 (45.2) 8/15 (53.3) 6/15 (40.0) 0.72
Prior stroke 4/31 (12.9) 3/15 (20.0) 1/15 (6.7) 0.60
Prior CABG 12/31 (38.7) 6/15 (40.0) 6/15 (40.0) 1.00
Prior AVR 16/31 (51.6) 8/15 (53.3) 8/15 (53.3) 1.00
TAVR 3/16 (18.8) 2/8 (25.0) 1/8 (12.5) 1.00
SAVR 13/16 (81.3) 6/8 (75.0) 7/8 (87.5) 1.00
Prior MV balloon valvuloplasty 4/31 (12.9) 1/15 (6.7) 3/15 (20.0) 0.60
STS score for MVR 6.3 (5.0–8.8) 6.4 (5.4–8.8) 6.2 (4.8–8.7) 0.82
NYHA functional class 0.01
I 0/31 (0.0) 0/15 (0.0) 0/15 (0.0)
II 4/31 (12.9) 4/15 (26.7) 0/15 (0.0)
III 22/31 (71.0) 11/15 (73.3) 11/15 (73.3)
IV 5/31 (16.1) 0/15 (0.0) 4/15 (26.7)
Values are median (interquartile range) or n/N (%). *Includes 1 transapical case not shown in transatrial or transseptal column. †Transatrial versus transseptal.
AVR ¼ aortic valve replacement; CABG ¼ coronary artery bypass grafting; MV ¼ mitral valve; MVR ¼ mitral valve replacement; NYHA ¼ New York Heart Association;
SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.






(n ¼ 15) p Value†
Ejection fraction (%) 63.1 (55.1–66.9) 64.8 (57.6–67.1) 61.3 (52.6–66.4) 0.66
Stroke volume (ml) 59.5 (49.2–80.5) 76.1 (54.9–86.8) 55.0 (48.9–70.7) 0.16
Cardiac output (l/min) 4.6 (3.7–6.2) 4.7 (4.2–6.7) 4.2 (3.7–6.0) 0.46
Mean MVG (mm Hg) 10.0 (7.6–12.8) 8.1 (7.3–11.8) 11.1 (8.2–13.9) 0.17
MVA (cm2)‡ 2.3 (1.8–2.9) 2.4 (1.7–3.2) 2.1 (1.8–2.5) 0.55
Pulmonary artery systolic pressure (mm Hg)§ 53.1 (45.0–66.0) 53.5 (51.9–72.2) 49.7 (44.7–56.2) 0.31
Peak LVOT gradient (mm Hg) 4.5 (3.1–6.9) 5.5 (2.8–7.9) 4.4 (3.6–6.8) 0.76
Mean LVOT gradient (mm Hg) 2.7 (1.7–3.9) 2.9 (1.5–4.2) 2.4 (2.0–3.7) 0.97
Mitral valve pathology 0.10
Stenosis (1 transapical) 23/31 (74.2) 9/15 (60.0) 13/15 (86.7)
Regurgitation 3/31 (9.7) 3/15 (20.0) 0/15 (0.0)
Both stenosis and regurgitation 5/31 (16.1) 3/15 (20.0) 2/15 (13.3)
Severity of mitral regurgitation 0.02
None or trace (1 transapical) 6/31 (19.4) 2/15 (13.3) 3/15 (20.0)
1 (þ) 11/31 (35.5) 2/15 (13.3) 9/15 (60.0)
2 (þ) 4/31 (12.9) 3/15 (20.0) 1/15 (6.7)
3 (þ) 8/31 (25.8) 7/15 (46.7) 1/15 (6.7)
4 (þ) 2/31 (6.4) 1/15 (6.7) 1/15 (6.7)
Values are median (interquartile range) or n/N (%). *Includes 1 transapical case not shown in the transatrial or transseptal column. †Transatrial versus transseptal. ‡Uncertain
reliability; echocardiographic methods validated in rheumatic disease and not mitral annular calcification. §7 missing values.
LVOT ¼ left ventricular outflow tract; MVA ¼ mitral valve area; MVG ¼ mitral valve gradient.
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(n ¼ 15) p Value†
Device 1.00
SAPIEN XT (1 transapical) 2/31 (6.5) 0/15 (0.0) 1/15 (6.7)
SAPIEN 3 29/31 (93.5) 15/15 (100.0) 14/15 (93.3)
Device size 0.39
23 mm 3/31 (9.7) 2/15 (13.3) 1/15 (6.7)
26 mm (1 transapical) 9/31 (29.0) 2/15 (13.3) 6/15 (40.0)
29 mm 19/31 (61.3) 11/15 (73.3) 8/15 (53.3)
Access NA
Transapical 1/31 (3.2) 0/15 (0.0) 0/15 (0.0)
Direct open transatrial 15/31 (48.4) 15/31 (48.4) 0/15 (0.0)
Transseptal 15/31 (48.4) 0/15 (0.0) 15/31 (48.4)
Traditional (wire free in left ventricle) 14/15 (93.3) 0/15 (0.0) 14/15 (93.3)
Modified (wire externalized through percutaneous sheath in left ventricle) 1/15 (6.7) 0/15 (0.0) 1/15 (6.7)
Pre-dilation or balloon sizing 6/31 (19.4) 2/15 (13.3) 4/15 (26.7) 0.65
Additional contrast during initial deployment 1.00
No 14/31 (45.2) 7/15 (46.7) 7/15 (46.7)
Yes (1 transapical) 17/31 (54.8) 8/15 (53.3) 8/15 (53.3)
Additional contrast volume, ml 3.0 (0.0–4.0) 3.0 (0.0–4.0) 4.0 (2.0–6.0) 0.07
Post-dilation (none in transapical) 10/31 (32.3) 2/15 (13.3) 8/15 (53.3) 0.05
Septostomy closed in transseptal cases during index procedure‡ 3/15 (20.0) 0/15 (0.0) 3/15 (20.0) 1.00
Results
In-hospital mortality (1 transapical) 5/31 (16.1) 3/15 (20.0) 1/15 (6.7) 0.60
Cardiovascular (1 transapical) 4/31 (12.9) 2/15 (13.3) 1/15 (6.7) 1.00
Noncardiovascular 1/31 (3.2) 1/15 (6.7) 0/15 (0.0) 1.00
Technical success at exit from catheterization lab 23/31 (74.2) 11/15 (73.3) 12/15 (80.0) 1.00
LVOTO with hemodynamic compromise 3/31 (9.7) 1/15 (6.7) 1/15 (6.7) 1.00
Need for a second valve§ 1/31 (3.2) 0/15 (0.0) 1/15 (6.7) 1.00
$2 (þ) residual MR (1 transapical) 4/31 (12.9) 2/15 (13.3) 1/15 (6.7) 1.00
LV perforation 1/31 (3.2) 1/15 (6.7) 0/15 (0.0) 1.00
Pericardial effusion requiring pericardiocentesis 1/31 (3.2) 0/15 (0.0) 1/15 (6.7) 1.00
Ventricular septal defect (myectomy in transatrial TMVR) 1/31 (3.2) 1/15 (6.7) 0/15 (0.0) 1.00
New pacemaker requirement (1 transapical) 5/31 (16.7) 2/15 (13.3) 2/15 (13.3) 1.00
Valve embolization 0/31 (0.0) 0/15 (0.0) 0/15 (0.0) NA
Conversion to open heart surgery 0/31 (0.0) 0/15 (0.0) 0/15 (0.0) NA
Paravalvular leak closure 0/31 (0.0) 0/15 (0.0) 0/15 (0.0) NA
Myocardial infarction requiring intervention 0/31 (0.0) 0/15 (0.0) 0/15 (0.0) NA
Major vascular complications (1 transapical) 1/31 (3.2) 0/15 (0.0) 0/15 (0.0) NA
Echocardiographic characteristics post-TMVR
Mean MVG (mm Hg) 2.8 (2.1–3.8) 2.8 (2.1–3.9) 2.7 (2.2–3.5) 0.61
MVA (cm2) 3.2 (2.7–3.4) 2.7 (2.6–3.5) 3.2 (3.0–3.4) 0.21
Peak LVOT gradient (mm Hg)‡ 6.3 (4.2–8.8) 6.5 (4.8–10.9) 6.3 (4.2–7.0) 0.50
Mean LVOT gradient (mm Hg)|| 3.5 (2.1–4.5) 3.0 (2.3–4.8) 3.6 (1.9–3.7) 0.82
Residual total MR 1.00
Trace or none 10/31 (32.3) 5/15 (33.3) 5/15 (33.3)
1 (þ) 17/31 (54.8) 8/15 (53.3) 9/15 (60.0)
2 (þ) 3/31 (9.7) 2/15 (13.3) 1/15 (6.7)
$3 (þ) (1 transapical) 1/31 (3.2) 0/15 (0.0) 0/15 (0.0)
Amount of paravalvular MR 0.89
Trace or none 14/31 (45.2) 8/15 (53.3) 6/15 (40.0)
1 (þ) 14/31 (45.2) 6/15 (40.0) 8/15 (53.3)
2 (þ) 2/31 (6.5) 1/15 (6.7) 1/15 (6.7)
$3 (þ) (1 transapical) 1/31 (3.2) 0/15 (0.0) 0/15 (0.0)
Values are n/N (%) or median (interquartile range). *Includes 1 transapical case not shown in transatrial or transseptal column. †Transatrial vs. transseptal. ‡1 for hypoxemia due to a right-to-
left shunt and 2 for significant left-to-right shunts at the discretion of the operator. All Amplatzer Septal Occluder device. §Due to excessive atrial positioning causing mitral regurgitation.
||10 missing values.
LV ¼ left ventricular; LVOTO ¼ left ventricular outflow tract obstruction; MR ¼ mitral regurgitation; NA ¼ not applicable; TMVR ¼ transcatheter mitral valve replacement; other abbre-
viations as in Tables 1 and 2.
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replacement. The median Society of Thoracic Sur-
geons Predicted Risk of Mortality score was 6.3%
(IQR: 5.0% to 8.8%) with a mean of 8.6  8.2%
(transatrial 7.8  4.2%, transseptal 9.9  11.0%),
p ¼ 0.50), and most patients were in New York Heart
Association functional class III or IV (transatrial,
73.3%; transseptal, 100%; p ¼ 0.01). Baseline echo-
cardiographic characteristics are described in Table 2.
Left ventricular function was normal. MS was the
predominant pathology and was present in 74.2%.
Transseptal access was used for 15 patients
(48.4%), transatrial for 15 patients (48.4%), and
transapical for 1 patient (3.2%). Selection of trans-
atrial access was based on the risk for embolization
(n ¼ 6), risk for LVOTO (n ¼ 3), or both (n ¼ 6). One
patient was treated via transapical access because of
challenging anatomy for transseptal access. Proce-
dural results are shown in Table 3.
PRIMARY SAFETY ENDPOINTS AND ACUTE RESULTS.
The primary safety endpoint of technical success at
exit from the procedure room was 74.2% (transatrial,
73.3% [11 of 15]; transseptal, 80.0% [12 of 15];
p ¼ 1.00). Reasons for not meeting technical success
criteria in 4 transatrial cases included LVOTO,
MR $2þ, wire-induced left ventricular perforation,
and ventricular septal defect due to concomitant
surgical myectomy. Reasons in the 3 transseptal cases
were LVOTO, MR $2þ, and need for a second valve.
There were no cases of valve embolization, need for
conversion to open heart surgery, or deaths during
the index procedures. The median hospital stay was
8.5 days (IQR: 4.25 to 12.75 days).
There were 5 in-hospital deaths (16.1%), which
included 3 patients who were treated via transatrial
access (3 of 15 [20%]). One patient who underwent
transapical access died. The case was complicated by
LVOTO, and the patient was treated the following day
with surgical explantation of the THV and redo
ViMAC with transatrial access and surgical resection
of the anterior leaflet. The other remaining in-
hospital death was the first patient treated in the
trial. That patient underwent transseptal ViMAC (1 of
15 [6.7%]) (p ¼ 0.60) and had LVOTO with hemody-
namic compromise, as detailed later.
LVOTO AND PRE-EMPTIVE ALCOHOL SEPTAL
ABLATION. LVOTO with hemodynamic compromise
occurred in 3 patients (transseptal, n ¼ 1; transapical,
n ¼ 1; transatrial, n ¼ 1). Outcomes of these patients
are summarized in Supplemental Appendix 6.
After the second patient was treated in this trial, we
began to use pre-emptive alcohol septal ablation in
patients at risk for TMVR-induced LVOTO. Seven of the
remaining 14 patients treated with transseptal access
were at high risk for LVOTO (median neo-LVOT area
100.0 mm2; IQR: 87.9 to 145.0 mm2) and underwent
pre-emptive alcohol septal ablation using 1.0 ml (IQR:
0.65 to 2.0 ml) of alcohol. Baseline echocardiographic
characteristics of these patients are summarized in
Table 4. Repeat CT scans 45 days (IQR: 23 to 50 days)
after alcohol septal ablation showed decreased risk
(median neo-LVOT area 227.5 mm2; IQR: 215.5 to
311.2 mm2), and all underwent successful transseptal
ViMAC (Figure 3). Three of the patients treated via
transatrial access also underwent pre-emptive alcohol
septal ablation (median 1.6 ml; IQR: 1.1 to 2.0 ml)
before transatrial ViMAC (median neo-LVOT area
50.9 mm2; IQR: 0 to 119.3 mm2) to avoid the need for
surgical myectomy during the same procedure.
ADDITIONAL ENDPOINTS. The primary performance
endpoint was achieved for 88% of survivors at
30 days (22 of 25) and for 100% of patients alive who
had echocardiographic data available (18 of 18) at 1
year. All-cause mortality at 30 days was 16.7%
(transatrial, 21.4%; transseptal, 6.7%; p ¼ 0.33) and at
1 year was 34.5% (transatrial, 38.5% [5 of 13]; trans-
septal, 26.7% [4 of 15]; p ¼ 0.69). Kaplan-Meier sur-
vival curves are shown in the Central Illustration.
THIRTY-DAY OUTCOMES. At 30 days, 25 of 30 pa-
tients (83.3%) were alive, and 60% were in New York
TABLE 4 Baseline Echocardiographic Characteristics of Patients Treated With
Transseptal Access After Implementing Preemptive ASA (n ¼ 14)
Trans-septal
No ASA (n ¼ 7) ASA (n ¼ 7) p Value
Ejection fraction (%) 65.0 (57.1–69.0) 55.6 (52.6–60.0) 0.44
Stroke volume (ml) 55.6 (50.0–70.6) 55.0 (48.8–73.9) 0.92
Cardiac output (l/min) 5.7 (3.7–5.7) 4.2 (3.8–6.2) 0.47
Mean MVG (mm Hg) 12.3 (7.7–18.0) 10.6 (9.4–11.3) 0.57
MVA (cm2)* 1.9 (1.8–2.2) 2.5 (2.0–2.8) 0.28
Pulmonary artery systolic pressure (mm Hg)† 62.0 (53.8–68.5) 44.2 (34.8–46.5) 0.01
Peak LVOT gradient (mm Hg) 4.5 (4.0–6.8) 4.6 (2.6–8.2) 0.89
Mean LVOT gradient (mm Hg) 2.7 (2.1–3.7) 2.6 (1.5–4.5) 1.00
Mitral valve pathology 0.46
Stenosis 5 (71.4) 7 (100.0)
Regurgitation 0 (0.0) 0 (0.0)
Both stenosis and regurgitation 2 (28.6) 0 (0.0)
Severity of mitral regurgitation 0.27
None or trace 0 (0.0) 2 (28.6)
1 (þ) 6 (85.7) 3 (42.9)
2 (þ) 0 (0.0) 1 (14.3)
3 (þ) 0 (0.0) 1 (14.3)
4 (þ) 1 (14.3) 0 (0.0)
Values are median (interquartile range) or n/N (%). *Uncertain reliability; echocardiographic methods validated in
rheumatic disease and not mitral annular calcification. †3 missing.
ASA ¼ alcohol septal ablation; other abbreviations as in Table 2.
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Heart Association functional class I or II. Clinical
outcomes at 30 days are shown in Table 5 and echo-
cardiographic characteristics in Table 6. New-onset
acute kidney injury requiring new hemodialysis and
new-onset atrial fibrillation were more frequent in
transatrial cases (both 28.6% vs. 0%; p ¼ 0.04). The
need for blood transfusion in all transatrial cases was
procedure related, whereas the reason for blood
transfusion in the 6 transseptal cases was hemolytic
anemia (n ¼ 3) and gastrointestinal bleeding (n ¼ 3).
1-YEAR OUTCOMES. At 1-year follow-up (median 1.0
year; IQR: 1.0 to 1.2 year), 19 of 29 eligible patients
(65.5%) were alive (transatrial, 61.5%; transseptal,
73.3%; p ¼ 0.69), and 83.3% were in New York Heart
Association functional class I or II (transatrial, 87.5%;
transeptal, 80%; p ¼ 0.16).
Clinical outcomes at 1 year are summarized in
Table 7 and echocardiographic characteristics in
Table 8. Patients alive had significant improvements
in New York Heart Association functional class
(Central Illustration), distance walked in the 6-min
walk test (Figure 4), and quality-of-life scores
(Figure 5). THV function remained stable, with a me-
dian mean MV gradient of 6.4 mm Hg (IQR: 4.2 to
7.4 mm Hg) in transatrial cases and 6.1 mm Hg (IQR:
FIGURE 3 Cardiac CT Findings After Pre-Emptive Alcohol Septal Ablation and Transseptal Valve-in-MAC
(A) Baseline cardiac computed tomographic (CT) imaging shows thick septum (arrow). (B) After placement of a 29-mm virtual valve, the remaining space in the LVOT is
reduced (arrow). (C) Baseline neo-LVOT area during systole is 176 mm2. CT scan obtained 4 weeks after alcohol septal ablation shows (D) reduced thickness of the
basal septum (arrow), (E) residual space in the LVOT larger than baseline, and (F) predicted neo-LVOT area during systole of 250 mm2. (G) Fluoroscopy of a transseptal
ViMAC implantation using a 29-mm SAPIEN 3 valve prepared with 4 ml of additional contrast to flare the ventricular edge of the THV stent (yellow arrow), 80%
ventricular and 20% atrial in relation to the mitral annulus (white arrow). (H) CT image post-TMVR shows the SAPIEN 3 valve in the desired position. (I) Post-TMVR
CT image shows the actual neo-LVOT measurement of 182 mm2 (arrow). Abbreviations as in Figure 1 and 2.
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5.7 to 6.8 mm Hg) in transeptal cases (p ¼ 0.93)
(Figure 6), and all patients had 1þ or less total MR.
Five patients developed hemolytic anemia by 1
year (transatrial, 7.7% [1 of 13]; transseptal, 26.7% [4
of 15]; p ¼ 0.33). Three patients with trace para-
valvular leak developed hemolysis within 30 days.
One of these patients was treated with mitral valve-
in-valve. The paravalvular leak spontaneously
resolved in 2 patients, but they required transfusion.
Of the 2 additional patients who developed hemolysis
after 30 days, 1 was treated by paravalvular leak
closure, and 1 was treated conservatively.
The anticoagulation regimens and valve throm-
bosis summaries are described in Supplemental
Appendix 7. There were no late device embolization
or migration events or endocarditis.
DISCUSSION
This is the first prospective, multicenter, early feasi-
bility clinical trial with independent imaging core
laboratories and independent clinical events adjudi-
cation to evaluate the safety and feasibility of ViMAC
using balloon-expandable aortic THVs. The following
were the main findings: 1) transseptal ViMAC in
carefully selected patients was associated with 30-
day mortality lower than predicted by the Society of
Thoracic Surgeons score; 2) pre-emptive alcohol
CENTRAL ILLUSTRATION 30-Day and 1-Year Outcomes of Valve–in–Mitral Annular Calcification in the Mitral
Implantation of Transcatheter Valves Trial
Guerrero, M. et al. J Am Coll Cardiol Intv. 2021;14(8):830–45.
Early and late outcomes for functional capacity (New York Heart [NYHA] Association functional class) in the transatrial group (left) and transseptal group (right) and
for survival (middle). ViMAC ¼ valve–in–mitral annular calcification.
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septal ablation preformed 3 to 4 weeks before ViMAC
can prevent LVOTO during transseptal ViMAC in pa-
tients at high risk; 3) THVs performed adequately in
most patients, and these outcomes were maintained
at 1 year; and 4) ViMAC was associated with signifi-
cantly diminished symptoms, improved 6-min walk
distance, and improved quality-of-life scores.
Our results differ from those of prior retrospective
studies that showed ViMAC to be feasible but asso-
ciated with procedural complications and high 30-day
and 1-year mortality (4,5). Outcomes for our patients
improved significantly with careful patient selection
and strategies to decrease risk for TMVR-induced
LVOTO, such as pre-emptive alcohol septal ablation
performed weeks before transseptal ViMAC or surgi-
cal resection of the anterior leaflet during transatrial
ViMAC.
MORTALITY. At 1 year, all-cause mortality in the
entire cohort was 34.5%, lower than that reported in
prior registries (4,5). For patients treated via trans-
septal access, 1-year all-cause mortality was 26.7%.
This is a remarkable improvement from the 51.1%
mortality rate for transseptal cases in the TMVR in
MAC Global Registry (4) and is similar to 1-year
mortality for transcatheter MV edge-to-edge repair
procedures with the MitraClip (Abbott Vascular,
Santa Clara, California) reported for the United
States (10).
Compared with the outcomes of TMVR studies
evaluating THVs designed for the MV, the 30-day
(6.7%) and 1-year (26.7%) all-cause mortality rates of
transseptal ViMAC cases in this study were identical
to the 30-day (6%) and 1-year (26%) mortality rates
reported for the initial feasibility study of the






(n ¼ 15) p Value‡
All-cause mortality (1 transapical) 5/30 (16.7) 3/14 (21.4) 1/15 (6.7) 0.33
Cardiovascular (1 transapical) 4/30 (13.3) 2/14 (14.3) 1/15 (6.7) 0.60
Noncardiovascular 1/30 (3.3) 1/14 (7.1) 0/15 (0.0) 0.48
Device success 17/30 (56.7) 9/14 (64.3) 8/15 (53.3) 0.71
Procedural success 16/30 (53.3) 9/14 (64.3) 7/15 (46.7) 0.46
Primary performance endpoint in survivors at 30 days§ 22/25 (88.0) 10/11 (90.9) 12/14 (85.7) 1.00
Stroke|| (1 transapical) 2/30 (6.7) 1/14 (7.1) 0/15 (0.0) 0.48
Ischemic (1 transapical) 2/30 (6.7) 1/14 (7.1) 0/15 (0.0) 0.48
Hemorrhagic 0/30 (0.0) 0/14 (0.0) 0/15 (0.0) NA
Myocardial infarction requiring revascularization 0/30 (0.0) 0/14 (0.0) 0/15 (0.0) NA
Mitral valve reintervention after index procedure (MViV)¶ (1 transapical) 2/30 (6.7) 0/14 (0.0) 1/15 (6.7) 1.00
Septostomy closed in transseptal cases (3 during index procedure, 1 after index
procedure)
4/15 (26.7) NA 4/15 (26.7) NA
Acute kidney injury requiring hemodialysis (1 transapical) 5/30 (16.7) 4/14 (28.6) 0/15 (0.0) 0.04
Blood transfusion (1 transapical) 16/30 (53.3) 9/14 (64.3) 6/15 (40.0) 0.27
Major vascular complication (1 transapical) 1/30 (3.3) 0/14 (0.0) 0/15 (0.0) NA
New permanent pacemaker requirement (1 transapical) 5/30 (16.7) 2/14 (14.3) 2/15 (13.3) 1.00
New-onset atrial fibrillation (1 transapical) 5/30 (16.7) 4/14 (28.6) 0/15 (0.0) 0.04
New rehospitalization for heart failure 4/30 (13.3) 1/14 (7.1) 3/15 (20.0) 0.60
Device embolization or migration 0/30 (0.0) 0/14 (0.0) 0/15 (0.0)
Hemolytic anemia# 3/30 (10.0) 0/14 (0.0) 3/15 (20.0) 0.22
Valve thrombosis 0/30 (0.0) 0/14 (0.0) 0/15 (0.0) NA
Endocarditis 0/30 (0.0) 0/14 (0.0) 0/15 (0.0) NA
New York Heart Association functional class 0.33
I 6/25 (24.0) 2/11 (18.2) 4/14 (28.6)
II 9/25 (36.0) 6/11 (54.5) 3/14 (21.4)
III 8/25 (32.0) 2/11 (18.2) 6/14 (42.9)
IV 2/25 (8.0) 1/11 (9.1) 1/14 (7.1)
Values are n/N (%). *Includes 1 transapical case not shown in the transatrial or transseptal column. †1 withdrew consent at 8 days post-TMVR before discharge to physical
therapy center. ‡Transatrial vs. transseptal. §Reason for not meeting performance endpoint was mean mitral valve gradient of 10.2 mm Hg in a transatrial case as well as MR 2
(þ) and 3 (þ) in 2 transseptal cases. ||All during index hospitalization. ¶1 transseptal MViV for hemolytic anemia in a transseptal case and 1 transatrial valve-in-MAC for left
ventricular outflow tract obstruction and paravalvular leakage in the transapical case. #1 treated with MViV and 2 spontaneously resolved, but all required transfusion.
MAC ¼ mitral annular calcification; MViV ¼ mitral valve–in–valve; NA ¼ not applicable.
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Tendyne transcatheter valve system (Abbott Struc-
tural Heart, Santa Clara, California) (11) and similar to
or lower than the initial experience with the Intrepid
TMVR system (Medtronic, Redwood City, California),
which reported 30-day mortality of 14% and 1-year
mortality of 23.8% (12). However, these early feasi-
bility studies involved different patient populations
with mostly functional MR in noncalcified MVs. Tak-
ing into consideration that the MITRAL trial is an
early experience with a small number of patients,
achieving 1-year mortality similar to that shown for a
well-established and safe procedure such as trans-
catheter edge-to-edge MV repair or early experience
with TMVR is encouraging and demonstrates this to
be a treatment option for at least some patients in a
group that is otherwise difficult to treat.
LVOTO AND THE ROLE OF PRE-EMPTIVE ALCOHOL
SEPTAL ABLATION. The new concept of performing
pre-emptive alcohol septal ablation before TMVR was
instituted in this trial. We had previously described
the role of emergency percutaneous alcohol septal
ablation for acutely reducing TMVR-induced LVOTO,
which can be a lifesaving strategy (6). After imple-
menting pre-emptive alcohol septal ablation to
decrease the risk for LVOTO in patients at risk (after
the first 2 patients enrolled), 7 of the remaining 14
patients treated via transseptal access were consid-
ered to have a high risk for LVOTO and underwent
pre-emptive alcohol septal ablation 3 to 4 weeks
before TMVR. All of these patients underwent suc-
cessful transseptal ViMAC and were alive at 30 days.
The LAMPOON procedure (intentional laceration of
the anterior mitral leaflet to prevent LVOTO) was
developed after the MITRAL trial started and was not
used in this study. The 30-day mortality of patients
who had transseptal access in our study was lower
than the 13.3% mortality of transseptal ViMAC re-
ported in the LAMPOON (Intentional Laceration of
the Anterior Mitral Leaflet to Prevent Left Ventricular
Outflow Tract Obstruction During Transcatheter
Mitral Valve Implantation) trial (13). The number of
patients in these studies is small, therefore, mean-
ingful comparisons cannot be made.
ACCESS TYPE SELECTION PROCESS. Transseptal
access was preferred in patients with favorable anat-
omy who were considered to have low risk for valve
embolization and LVOTO. Risk for valve embolization
was assessed by analysis of calcium amount and dis-
tribution on cardiac CT imaging. This assessment was
initially descriptive. During the course of our study
and using data from the TMVR in MAC registry for
validation, a cardiac CT score was developed to
categorize MAC severity and predict valve emboliza-
tion. A MAC score of 6 or less was associated with a
very high (60%) risk for valve embolization or
migration (14). A MAC score of 7 or greater and a






(n ¼ 14) p Value†
Ejection fraction (%) 55.5 (50.7–66.2) 55.0 (48.9–65.3) 56.0 (51.5–66.2) 0.49
Stroke volume (ml) 65.3 (46.3–76.2) 76.4 (46.3–85.9) 62.3 (48.7–70.6) 0.14
Cardiac output (l/min) 5.1 (3.8–6.0) 5.6 (4.9–7.0) 4.9 (3.4–5.4) 0.11
Mean MVG (mm Hg) 6.0 (5.2–7.8) 7.4 (5.0–8.6) 5.9 (5.3–7.1) 0.44
MVA (cm2)‡ 2.9 (2.5–3.3) 2.9 (2.6–3.1) 2.9 (2.5–3.4) 0.89
Pulmonary artery systolic pressure (mmHg)§ 50.5 (41.6–69.9) 42.0 (38.9–64.0) 54.2 (47.9–70.3) 0.425
Peak LVOT gradient 7.2 (4.8–11.6) 7.2 (5.9–11.7) 6.8 (4.5–11.0) 0.41
Mean LVOT gradient 3.5 (2.7–6.1) 3.2 (3.1–6.8) 3.7 (2.6–6.0) 0.83
Severity of total mitral regurgitation 1.00
None to trace 17/25 (68.0) 8/11 (72.7) 9/14 (64.3)
1 (þ) 6/25 (24.0) 3/11 (27.3) 3/14 (21.4)
2 (þ) 1/25 (4.0) 0/11 (0.0) 1/14 (7.1)
$3 (þ) 1/25 (4.0) 0/11 (0.0) 1/14 (7.1)
Severity of paravalvular mitral regurgitation 0.15
None to trace 20/25 (80.0) 11/11 (100.0) 9/14 (64.3)
1 (þ) 3/25 (12.0) 0/11 (0.0) 3/14 (21.4)
2 (þ) 1/25 (4.0) 0/11 (0.0) 1/14 (7.1)
$3 (þ) 1/25 (4.0) 0/11 (0.0) 1/14 (7.1)
Values are median (interquartile range) or n/N (%). *At 30 days, 25 echocardiographic studies were available (5 patients died and 1 withdrew consent 8 days after valve-in-
MAC). †Transatrial vs. transseptal. ‡Uncertain reliability; standard echocardiographic methods are validated in rheumatic disease and not MAC or after TMVR. §8 missing values.
Abbreviations as in Tables 2, 3, and 5.
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neo-LVOT >190 mm2 were the main criteria for
selecting transseptal access in our study.
OTHER INTRAPROCEDURAL CHALLENGES. In contrast
to results from prior registries, no cases of valve
embolization occurred in this trial. In a registry report
by Yoon et al. (5), the valve embolization rate was
6.9%, and in the TMVR in MAC Global Registry, it was
4.3% (4). We attribute the absence of valve emboli-
zation in our study to careful cardiac CT analysis and
use of the CT MAC score to help predict valve
anchoring (14). At 30 days, hemolytic anemia was
present in 20% of transseptal cases (3 of 15) but no
transatrial cases. There was no correlation with large
paravalvular leak; these 3 patients with hemolytic
anemia had trace paravalvular leak at 30 days and had
none at 1 year. We suspect the higher flow velocity in
small paravalvular leak jets contributed to hemolysis
events in these patients. This hemolysis rate is higher
than the 3.8% rate reported in the TMVR in MAC
Global Registry, and it was not reported by Yoon et al.
(5). However, those were both retrospective studies,
and they may not have actively screened for and
captured hemolysis data, as was done in our study.
Possibly the newer design of the SAPIEN 3 Ultra may
help address this limitation.
THV PERFORMANCE ENDPOINT. The primary per-
formance endpoint of absence of MR grade 2þ or
greater or mean MV gradient $10 mm Hg was ach-
ieved in all patients alive with echocardiographic data
available at 1 year. We do not suspect that this is due
to survivorship bias. There were 5 deaths after
30 days. Three of those subjects met THV






(n ¼ 15) p Value‡
All-cause mortality (1 transapical) 10/29 (34.5) 5/13 (38.5) 4/15 (26.7) 0.69
Cardiovascular (1 transapical) 6/29 (20.7) 3/13 (23.1) 2/15 (13.35) 1.00
Noncardiovascular 4/29 (13.8) 2/13 (15.4) 2/15 (13.35) 0.58
Primary performance endpoint in survivors at 1 yr (1 missed echocardiography
study)
18/18 (100) 8/8 (100) 10/10 (100) 1.00
Stroke§ (1 transapical) 2/29 (6.9) 1/13 (7.7) 0/15 (0.0) 0.46
Ischemic (1 transapical) 2/29 (6.9) 1/13 (7.7) 0/15 (0.0) 0.46
Hemorrhagic 0/29 (0.0) 0/13 (0.0) 0/15 (0.0) NA
Myocardial infarction requiring revascularization 0/29 (0.0) 0/13 (0.0) 0/15 (0.0) NA
Mitral valve reintervention after index procedure (1 transapical)|| 4/29 (13.8) 1/13 (7.7) 2/15 (13.3) 1.00
Septostomy closed in transseptal cases (3 during index procedure, 2 after index
procedure)
5/15 (33.3) NA 5/15 (33.3) NA
Acute kidney injury requiring hemodialysis (1 transapical) 5/29 (17.2) 4/13 (30.8) 0/15 (0.0) 0.01
Blood transfusion (1 transapical) 17/29 (62.1) 9/13 (76.9) 7/15 (46.7) 0.14
Major vascular complication (1 transapical) 1/29 (3.4) 0/13 (0.0) 0/15 (0.0) NA
New permanent pacemaker requirement (1 transapical) 5/29 (17.2) 2/13 (15.3) 2/15 (13.3) 1.00
New-onset atrial fibrillation (1 transapical) 5/29 (17.2) 4/13 (30.7) 0/15 (0.0) 0.07
New rehospitalization for heart failure¶ 11/29 (37.9) 4/13 (30.8) 7/15 (46.7) 0.46
Device embolization or migration 0/29 (0) 0/13 (0.0) 0/15 (0.0) NA
Hemolytic anemia# 5/29 (17.2) 1/13 (7.7) 4/15 (26.7) 0.33
Valve thrombosis 1/29 (3.4) 0/13 (0.0) 1/15 (6.7) 1.00
Endocarditis 0/29 (0.0) 0/13 (0.0) 0/15 (0.0) NA
New York Heart Association functional class** 0.16
I 7/18 (38.9) 2/8 (25.0) 5/10 (50.0)
II 8/18 (44.4) 5/8 (62.5) 3/10 (30.0)
III 3/18 (16.7) 1/8 (12.5) 2/10 (20.0)
IV 0/18 (0.0) 0/8 (0.0) 0/10 (0.0)
Values are n/N (%). *Includes 1 transapical case not shown in the transatrial or transseptal column. †1 withdrew consent at 8 days after transatrial ViMAC before discharge to a
physical therapy center, and 1 withdrew consent at day 187 after transatrial ViMAC. ‡Transatrial vs. transseptal. §All during index hospitalization. ||2 within 30 days:
1 transseptal MViV for hemolysis and 1 transatrial valve-in-MAC for left ventricular outflow tract obstruction and paravalvular leakage after transapical ViMAC. 2 after 30 days:
both paravalvular leak closures (1 transatrial and 1 transseptal case). ¶The reason for heart failure was identified as volume overload in patients with pre-existing systolic
dysfunction in 1 and diastolic dysfunction in 3 of the transatrial cases. The reason in transseptal cases was diastolic heart failure in 3, aortic stenosis in 1, and mild paravalvular
leak in 1. It was thought to be attributable to persistent septostomy in 2 patients who underwent closure of an atrial septal defect during that admission. #3 cases at 30 days:
1 patient was treated with MViV, and 2 patients had spontaneous resolution, but all required transfusion. There were 2 additional cases of hemolytic anemia after 30 days: 1 was
treated with paravalvular closure and 1 conservatively. **1 missing value (1 patient alive at 1 year did not have a 1-year follow-up visit).
ViMAC ¼ valve-in-MAC; other abbreviations as in Tables 3 and 5.
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performance endpoint at 30 days and 2 did not
because of MR grade 2þ. These 2 subjects died of
noncardiovascular causes, subdural hematoma after
head trauma subsequent to a fall, and end-stage renal
disease on day 355 post-ViMAC. The latter underwent
1-year follow-up transthoracic echocardiography
prior to his death, which showed a mean MV gradient
of 5.8 mm Hg and 1þ MR, meeting the performance
FIGURE 4 6-Min Walk Test
IQR ¼ interquartile range.
TABLE 8 Echocardiographic Characteristics at 1 Year
All Patients* (N ¼ 18) Transatrial Access (n ¼ 8) Transseptal Access (n ¼ 10) p Value†
Ejection fraction (%) 65.3 (60.8–69.9) 68.4 (64.4–71.3) 64.5 (60.4–65.5) 0.18
Stroke volume (ml) 89.2 (62.8–94.5) 89.2 (69.9–94.2) 77.7 (60.9–98.9) 1.00
Cardiac output (l/min) 5.1 (4.5–7.4) 5.1 (4.7–6.8) 5.9 (4.4–7.7) 1.00
Mean MVG (mm Hg) 6.1 (5.6–7.1) 6.4 (4.2–7.4) 6.1 (5.7–6.8) 0.93
MVA (cm2)‡ 3.1 (2.6–3.9) 2.6 (2.3–3.0) 3.8 (3.0–4.1) 0.05
Pulmonary artery systolic pressure (mm Hg)§ 39.3 (35.0–48.3) 37.7 (26.7–48.3) 40.0 (36.8–52.1) 0.46
Peak LVOT gradient 5.3 (3.5–8.4) 6.8 (5.1–9.0) 4.2 (3.5–6.4) 0.27
Mean LVOT gradient 3.1 (2.2–4.9) 3.9 (2.8–5.1) 2.4 (2.2–4.1) 0.48
Severity of total mitral regurgitation 0.66
None to trace 10/18 (55.6) 5/8 (62.5) 5/10 (50.0)
1 (þ) 8/18 (44.4) 3/8 (37.5) 5/10 (50.0)
2 (þ) 0/18 (0) 0/8 (0) 0/10 (0)
$3 (þ) 0/18 (0) 0/8 (0) 0/10 (0)
Severity of paravalvular mitral regurgitation 0.48
None to trace 16/18 (88.9) 8/8 (100.0) 8/10 (80.0)
1 (þ) 2/18 (11.1) 0/8 (0.0) 2/10 (20.0)
2 (þ) 0/18 (0) 0/8 (0) 0/10 (0)
$3 (þ) 0/18 (0) 0/8 (0) 0/10 (0)
Values are median (interquartile range) or n/N (%). *At 1 yr, 18 echocardiographic studies were available: 10 patients died, 1 withdrew consent 8 days after transatrial TMVR, 1
withdrew consent 187 days after transatrial TMVR, and 1 patient alive at 1 yr did not have a 1-yr follow-up visit. †Transatrial vs. transseptal. ‡Uncertain reliability; standard
echocardiographic methods are validated in rheumatic disease and not for MAC or after TMVR. §5 missing values.
Abbreviations as in Tables 2, 3, and 5.
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endpoint. These results are encouraging considering
the round shape of the aortic THV and the oval saddle
shape of the native MV, which could result in more
residual paravalvular leak. Although the mean MV
gradient was higher than reported in THV designed
for the mitral position (6.1  1.6 mm Hg vs. 3.0 
1.1 mm Hg), the amount of residual MR was
similar (11).
FEMALE SEX. Most of the patients included in this
study were women (71%), unlike in many other
research trials, but the mostly female population is
similar to that of other prior MAC registry studies
(4,5). The reasons for this may be multifactorial,
including a higher prevalence of MAC in women and
higher surgical risk, resulting in women’s being
referred more often for TMVR.
STUDY LIMITATIONS. First, this was an early feasi-
bility study with a small number of patients enrolled.
Because it was not randomized and controlled, the
results cannot provide evidence that MV intervention
FIGURE 5 Quality-of-Life Score
IQR ¼ interquartile range; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire.
FIGURE 6 Mean Mitral Valve Gradient
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in patients with advanced MV dysfunction attribut-
able to MAC is associated with decreased mortality.
Similarly, assignment to access type was not ran-
domized; therefore, difference in outcomes among
access types can only generate hypotheses. In addi-
tion, outcomes of patients who were not accepted in
the trial were not collected. Therefore, data on the
natural history of these patients is unknown.
Second, the outcomes of septal ablation proced-
ures performed outside the trial in preparation for
possible patient enrollment were not collected. Pa-
tients may have undergone alcohol septal ablation
that resulted in poor outcomes, and their cases were
never presented for enrollment in this study. Alcohol
septal ablation was the only LVOTO risk reduction
strategy used in transseptal cases. Percutaneous
laceration of the anterior leaflet with the LAMPOON
procedure was developed after the MITRAL trial was
initiated and not used in this study. Therefore, safety
of these 2 important strategies was not compared.
Finally, the patient population in our study was
highly selected, with the initial screen failure rate at 2
to 1. Therefore, our results cannot be applied to the
general population.
NEXT STEPS. Further studies are needed to refine the
patient selection process and standardize the trans-
septal ViMAC technique. The MITRAL II pivotal trial
will evaluate the safety and effectiveness of trans-
septal ViMAC with the SAPIEN 3 Ultra THV
(NCT04408430) in patients at high surgical risk.
CONCLUSIONS
ViMAC was associated with significant alleviation of
symptoms and improvement in quality of life as well
as stable THV performance at 1 year. TMVR-induced
LVOTO can be prevented with pre-emptive alcohol
septal ablation in patients at risk. In patients treated
with transseptal access, 30-day mortality was lower
than predicted by the Society of Thoracic Surgeons
score, and 1-year mortality was similar to that re-
ported for transcatheter MV repair and replacement
populations. Further studies are needed to evaluate
the safety and efficacy of ViMAC.
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PERSPECTIVES
WHAT IS KNOWN? Patients with severe MAC often
have high surgical risk. TMVR is emerging as an
alternative for these patients.
WHAT IS NEW? High-risk patients with severe MAC
and MV dysfunction who were treated with a ViMAC
procedure had significant reduction of symptoms and
improvement in quality of life, as well as stable THV
performance at 1 year. Alcohol septal ablation per-
formed 3 to 4 weeks before TMVR can decrease the
risk for TMVR-induced LVOTO and facilitate safe
transseptal ViMAC in patients who were previously
ineligible because of this risk.
WHAT IS NEXT? Further studies are needed to
confirm the safety and efficacy of ViMAC, refine pa-
tient selection to improve technical success, and
evaluate longer term outcomes.
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APPENDIX For inclusion and exclusion
criteria, trial operations, supplemental
methods, study endpoints, outcomes, and
supplemental references, please see the online
version of this paper.
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